Humacyte director buys 11,000 shares in open market

Humacyte, Inc. director Michael T. Constantino reported an open-market purchase of common stock.

Rhea-AI Filing Summary

Humacyte, Inc. director Michael T. Constantino reported an open-market purchase of common stock. On May 18, 2026, he bought 11,000 shares of Humacyte common stock at a weighted average price of $0.8945 per share in multiple transactions.

Following this purchase, Constantino directly owns 43,950 common shares. The filing notes that the trades were executed across a price range from $0.8922 to $0.8958 per share and that detailed trade-by-trade pricing is available upon request.

Insider Trade Summary

Net Buyer: 11,000 shares

Net Buy 1 txn

Insider Constantino Michael T.

Role Director

Bought 11,000 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	11,000	$0.8945	$10K

Holdings After Transaction: Common Stock — 43,950 shares (Direct)

Footnotes (1)

1. F1. The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.8922 to $0.8958. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 11,000 shares Weighted average price: $0.8945 per share Price range: $0.8922–$0.8958 per share +2 more

5 metrics

Shares purchased 11,000 shares Open-market purchase of Humacyte common stock on May 18, 2026

Weighted average price $0.8945 per share Average price paid for 11,000 shares

Price range $0.8922–$0.8958 per share Range of prices across multiple purchase transactions

Shares owned after 43,950 shares Director’s direct Humacyte common stock holdings after the purchase

Net buy shares 11,000 shares Net change in common stock from this Form 4 (net buy)

Key Terms

open-market purchase, weighted average price, Reporting Person

3 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price is a weighted average price. The shares were purchased"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Reporting Person regulatory

"The Reporting Person undertakes to provide upon request"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Humacyte (HUMA) disclose in this Form 4?

Humacyte (HUMA) disclosed that director Michael T. Constantino completed an open-market purchase of company stock. He bought 11,000 shares of Humacyte common stock on May 18, 2026, and reported the transaction in a Form 4 insider trading filing.

How many Humacyte (HUMA) shares did the director buy and at what price?

The Humacyte (HUMA) director purchased 11,000 common shares. The filing reports a weighted average purchase price of $0.8945 per share, with individual trades executed within a price range from $0.8922 to $0.8958 across multiple transactions on the same date.

How many Humacyte (HUMA) shares does the director own after this transaction?

After the reported purchase, the Humacyte (HUMA) director directly owns 43,950 common shares. This total reflects his holdings immediately following the 11,000-share open-market purchase disclosed in the Form 4 and represents his current reported direct ownership position.

Was the Humacyte (HUMA) insider trade an open-market purchase?

Yes. The Form 4 describes the Humacyte (HUMA) transaction as an open-market purchase. It is coded as transaction type “P,” with the narrative indicating that the 11,000 shares of common stock were bought in open-market transactions at prices near $0.89 per share.

What does the weighted average price mean in the Humacyte (HUMA) Form 4?

The weighted average price in the Humacyte (HUMA) Form 4 shows the average price paid across multiple small trades. For this transaction, shares were bought between $0.8922 and $0.8958, resulting in a reported weighted average purchase price of $0.8945 per share for 11,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 04:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Constantino Michael T.

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		P		11,000	A	$0.8945(1)	43,950	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.8922 to $0.8958. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Michael T. Constantino by Dale A. Sander as Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)